Anthocyanin intake linked to lower cardiovascular and metabolic disease risk in healthy adults

Across the cohort studies, people with the highest anthocyanin intake had a 26% lower risk of cardiovascular disease incidence, 18% lower myocardial infarction risk, 11% lower type 2 diabetes risk, and 9% lower cardiovascular mortality compared to those with the lowest intake. The GRADE assessment rated this evidence as moderate for CVD and MI. In the controlled trials, both acute (single-dose) and chronic (≥1 day) anthocyanin interventions improved flow-mediated dilation—a measure of blood vessel function and atherosclerosis risk—by roughly 1.4–1.5 percentage points, with strong evidence for acute dosing. Delphinidin (a specific anthocyanin type) showed benefits across multiple markers: it improved blood vessel stiffness and lowered insulin and triglycerides, whereas cyanidin improved chronic blood vessel function. However, the trials found no significant effect on blood pressure, lipids overall, or fasting glucose in healthy participants. The study included diverse populations and settings, though generalizability to severely diseased groups remains unclear.

The cohort data showed consistent dose–response patterns: each additional serving or anthocyanin-rich food category tracked tended to confer additive protection. Notably, stroke risk was not affected across studies—a limitation that suggests anthocyanins' benefits may be selective to atherosclerotic pathways rather than all vascular threats. Delphinidin's superiority across biomarkers hints at mechanism: it may work through improved vascular compliance and insulin secretion, not just endothelial nitric oxide production. Cyanidin's specificity to chronic blood vessel dilation (not acute) implies different kinetics or targets. The RCT evidence is particularly strong for acute FMD (95% confidence interval excluding zero and GRADE rating 'strong'), but chronic improvements were modest in absolute terms (1.41 percentage points on a typical 3–5 percentage point baseline FMD), requiring several weeks of consistent intake. Subgroup analyses by age, sex, baseline health status, and anthocyanin source (whole food vs. extract) were either sparse or not reported, limiting confidence in personalized recommendations. The disconnect between cohort CVD risk reduction (26%) and RCT biomarker improvements (1.4% FMD) may reflect unmeasured confounding in observational data or long-term cumulative effects not captured in shorter trials.